Namyang Dairy chairman files answer with court just before deadline Answer submitted four months after Hahn & Co filed lawsuit against Hong won-sik
Translated by Ryu Ho-joung 공개 2022-01-05 08:11:28
이 기사는 2022년 01월 05일 08시07분 thebell에 표출된 기사입니다
Hong Won-sik, owner and chairman of Namyang Dairy Products, submitted a written answer to a court through his representing law firm LKB& Partners just before the deadline set by a judge in the first hearing.The answer was filed with the Seoul Central District Court on December 31, more than four months after private equity firm Hahn & Company filed a lawsuit in August last year against Hong and his family demanding the execution of the share purchase agreement between the two parties.
Hong’s slow response is seen by some legal experts as a tactical move to postpone the trial. During the first hearing, which was held on December 2, an attorney representing Hong and his family said the filing of the answer could be completed by the next hearing date.
But the judge did not accept this and asked the defendants to submit the answer within 30 days after the first hearing date.
According to the information filed with the court by LKB& Partners on December 31, an additional attorney at the law firm joined the case.
Hong has yet to inform the court of whether he has hired an additional law firm, which was cited as one of the reasons for the delay of the defendant answer in the first hearing.
Legal sources said Hong has consulted a law firm that specializes in cases involving mergers and acquisitions and corporate ownership apart from LKB& Partners.
A second hearing is scheduled for January 13. (Reporting by Gyoung-tae Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '비상경영체 돌입' SKT, 유심 사태 수습 '총력전'
- 위메이드 "위믹스 해킹 늑장공시 아니야…DAXA 기준 불분명"
- [Market Watch]DN솔루션즈 이어 롯데글로벌까지, 대형 IPO '휘청'
- [롯데글로벌로지스 IPO]흥행 실패 우려, 결국 상장 철회로 귀결
- [AACR 2025]제이인츠 'JIN-001', 독성 최소화한 '저농도' 효능 입증
- [Financial Index/SK그룹]주가상승률 50% 상회, SK스퀘어 'TSR' 그룹내 최고
- 금호타이어, 분기 '최대 매출'…영업이익은 '주춤'
- 유지한 SKC CFO "트럼프 관세, 위기보다 기회"
- [i-point]신테카바이오, 'K-BioX 글로벌 SUMMIT 6' 참여
- 간추려진 대명소노그룹 선택지, '티웨이'에 집중